StockNews.AI

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

StockNews.AI • 3 hours

BFRI
High Materiality9/10

Information

Fourth quarter results represent highest quarterly revenue in Company's history Q4 year-over-year gr...

Original source

AI Summary

Biofrontera Inc. (BFRI) anticipates a record fourth quarter revenue of up to $17.5 million, reflecting strong Ameluz® sales and a promising outlook for 2025. The company expects full-year revenues to grow by 11% to 13%. This strong performance may enhance investor confidence and stock value ahead of detailed financial disclosures in March 2026.

Sentiment Rationale

The record revenues suggest strong market execution and customer traction, correlating with potential upward price movement similar to past quarterly earnings surprises in biotech.

Trading Thesis

Bullish on BFRI based on strong quarterly performance and growth outlook.

Market-Moving

  • Record quarterly revenue may boost investor sentiment significantly.
  • Anticipation of full-year results could drive stock momentum.
  • Strong demand and customer engagement could lead to sustained growth.
  • Expected shareholder presentations may result in increased visibility and interest.

Key Facts

  • BFRI reports highest quarterly revenue of $17.0M to $17.5M.
  • Fourth quarter growth of 35% to 39% driven by Ameluz® sales.
  • Full year 2025 revenue forecasted at $41.5M to $42.0M.
  • CEO confident about ongoing product adoption and operational improvements.
  • Final financial results to be announced in March 2026.

Companies Mentioned

  • Biofrontera AG (N/A): Transformation improves gross margin and strengthens BFRI’s financial foundation.

Corporate Developments

This fits into 'Corporate Developments' as it relates to BFRI's financial performance and strategic direction, which impacts investor perception and valuation.

Biofrontera Inc. Reports Record Fourth Quarter 2025 Revenues

WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a front-runner in photodynamic therapy (PDT) development, has announced preliminary unaudited revenue results for the fourth quarter of 2025. The company confirms estimated revenues between $17.0 million and $17.5 million, marking the highest quarterly revenue in its history and a significant year-over-year growth of approximately 35% to 39% driven by strong sales of its product, Ameluz®.

Full Year Financial Performance

The anticipated revenue for Biofrontera for the full year 2025 is projected to be within the range of $41.5 million to $42.0 million, reflecting an overall year-over-year growth of 11% to 13%. The company will disclose complete financial results for the fourth quarter and the full year in March 2026.

CEO Comments on Performance

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, stated, “We are very pleased with our fourth quarter performance which was driven by strong execution across the business, continued growth of Ameluz® PDT and the pricing adjustment introduced in December.” He emphasized that customer adoption remained strong, significantly contributing to the record revenue performance and validating the company’s strategic approach as it prepares for robust momentum into 2026.

Recent Transformational Transactions

Luebbert further noted that a recent transformative transaction with Biofrontera AG is expected to enhance the company's gross margin profile and strengthen its financial foundation. “We’ve never been more energized about the year ahead, and we’re confident that our innovative products, operational excellence, and unwavering commitment to customers will drive continued, sustainable growth,” he added.

Future Reporting and Investor Engagement

The preliminary figures mentioned above are subject to change pending finalization of the company’s financial statements. Biofrontera will present its complete fourth quarter and full year financial results in March 2026, with details of the announcement and a conference call to be provided in the coming weeks. Additionally, Biofrontera management will participate in the Lytham Partners Healthcare Investor Summit on January 15, 2026.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions, focusing on photodynamic therapy. The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series, targeting Actinic Keratosis, pre-cancerous skin lesions known to evolve into invasive skin cancers. Further clinical trials are in progress to explore the use of its products for treating non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com or follow Biofrontera on LinkedIn and X.

Forward-Looking Statements

Statements in this article may include “forward-looking statements” under the United States Private Securities Litigation Reform Act of 1995. These include, but are not limited to, expectations regarding Biofrontera's financial results and future growth potentials. However, actual results may differ materially due to various risks and uncertainties, including those associated with ongoing clinical trials and market conditions. Readers are cautioned not to place undue reliance on these statements.

Related News